The present invention relates generally to the detection of extravasation of fluids injected into a patient, and, more particularly, to extravasation detection apparatuses, systems and methods in medical injection procedures using energy transmission through tissue in the vicinity of an injection site or other site.
In many medical diagnostic and therapeutic procedures, a physician or other person injects a patient with a fluid. In recent years, a number of injector-actuated syringes and powered injectors for pressurized injection of contrast medium in procedures such as angiography, computed tomography, ultrasound and NMR/MRI have been developed.
Extravasation is the accidental infusion of an injection fluid such as a contrast medium into tissue surrounding a blood vessel rather than into the blood vessel itself. Extravasation can be caused, for example, by fragile vasculature, valve disease, inappropriate needle placement, or patient movement resulting in the infusing needle being pulled from the intended vessel or causing the needle to be pushed through the wall of the vessel. Furthermore, high injection pressures and/or rates of some modern procedures increase the risk of extravasation. In computed tomography, for example, contrast injection flow rates can be in the range of 0.1 to 10 ml/s.
Moreover, extravasation can cause serious injury to patients. In that regard, certain injection fluids such as contrast media or chemotherapy drugs can be toxic to tissue if not diluted by blood flow. It is, therefore, very important when performing fluid injections to detect extravasation as soon as possible and discontinue the injection upon detection.
Several extravasation techniques are known in the art. Two simple and very useful techniques for detecting extravasation are palpation of the patient in the vicinity of the injection site and simple visual observation of the vicinity of the injection site by a trained health care provider. In the palpation technique, the health care provider manually senses swelling of tissue near the injection resulting from extravasation. By visual observation, it is also sometimes possible to observe directly any swelling of the skin in the vicinity of an injection site resulting from extravasation.
In addition to palpation and observation, there are a number of automated methods of detecting extravasation that may include automatic triggering of an alarm condition upon detection. Unfortunately, each of these automated methods of detecting extravasation is limited by significant drawbacks.
U.S. Pat. No. 4,647,281, for example, discloses subcutaneous temperature sensing of extravasation to trigger an alarm. In this method of extravasation detection, an antenna and a microwave radiometer instantaneously measure the temperature of the subcutaneous tissue at the site where fluid is injected. An algorithm periodically determines the temperature difference between the tissue and the injected fluid, and compares the difference to a fixed threshold. An alarm processor uses the comparison to determine an alarm condition.
In addition, U.S. Pat. No. 5,334,141 discloses a microwave extravasation detection system employing a reusable microwave antenna and a disposable attachment element for releasably securing the microwave antenna to a patient's skin over an injection site. The attachment element holds the antenna in intimate contact with the patient's skin to optimize microwave transfer therebetween, while shielding the antenna from environmental noise signals. Although measurement of temperature changes and emissivity using microwave energy can result in instantaneous detection, temperature differences are often too small for practical measurement.
Several plethysmographic detection techniques are available in addition to known temperature sensing techniques. For example, mercury strain gauge plethysmographs measure the volume change resulting from venous blood flow in a cross-sectional area of a limb of a patient. Air cuff or pulse volume recorder plethysmographs measure the changes in pressure within a recording cuff caused by the change in volume of a limb or digit as a result of extravasation. Such plethysmographs can be cumbersome to operate and/or insensitive to small changes in volume.
Photo-plethysmographs measure the optical scattering properties of capillary blood to detect the presence of extravasated fluids in tissue. An example of a photo-plethysmograph is described in U.S. Pat. No. 4,877,034. Because light is heavily absorbed in tissue, however, the sensitivity of photo-plethysmographs is generally limited to the top ¼ inch to ½ inch of tissue. Most extravasations, however, occur deeper than ¼ inch to ½ inch. Moreover, the injection medium may flow into interstitial spaces remote from the photo-plethysmograph sensors and go undetected.
Impedance plethysmographs measure changes in the electrical impedance in a defined tissue volume of a limb. In this method, an impedance change of a certain level in the vicinity of the injection site is interpreted as being an extravasation. A change in impedance occurs during extravasation because injection fluid in the tissue of the patient changes both the volume and the electrical impedance properties of the tissue. Use of electrodes in impedance plethysmographs can, however, result in instabilities. For example, maintaining suitable electrical contact between the electrodes of impedance plethysmographs and the skin of the patient is often very difficult.
It is, therefore, very desirable to develop improved devices and methods for detecting extravasation during, for example, the high flow rate procedures (1 to 10 ml/sec) typically encountered in angiographic, CT, ultrasound, and MR imaging procedures.
Current automated methods for detecting extravasation do not take adequate advantage of the inherent or designed properties of the injection fluid. In the case of a contrast medium, for example, the contrast medium is designed to affect a certain type or types of applied energy (that is, the imaging energy) to provide an enhanced image of an internal region (sometimes referred to as a region of interest or ROI) of a patient. The inherent or designed properties of an injection medium can be used to provide a sensitive measurement of extravasation in real time.
In one embodiment, the present invention provides an apparatus for the detection of extravasation in an imaging procedure. Such imaging procedures typically include the steps of injecting a contrast medium into a patient and supplying imaging energy from a first source of imaging energy to a region of interest of the patient to create an image of the region of interest. As discussed above, this image is enhanced by the effect the contrast medium has upon the imaging energy in the region of interest. In general, the extravasation detection apparatus includes at least a second source of imaging energy to supply imaging energy to tissue in the vicinity of a site. The apparatus also includes at least one sensor to measure a signal resulting from the imaging energy supplied to the tissue by the second imaging energy source.
The apparatus of the present invention thus uses the inherent or designed properties of the contrast medium to detect extravasation of the contrast medium. For example, in the case of a contrast medium designed to be use in connection with a procedure in which X-rays are used as the imaging energy (for example, computed tomography or CT), the contrast medium is designed to absorb, block or scatter transmission of X-rays and low energy gamma rays. In this embodiment, a source of X-rays or gamma rays preferably provides a safely low level of such energy to a site on a patient's limb at which extravasation is to be detected (for example, the injection site). An energy sensor or detector that is suitable for detecting X-rays and/or gamma rays is preferably positioned on an opposing side of the limb from the energy source. The level of energy detected by the sensor provides an instantaneous and sensitive measurement of extravasation.
Other energy sources can be used in the present invention depending upon the properties of the contrast medium. Ultrasound imaging, for example, creates images of the human body by broadcasting ultrasonic energy into the body and analyzing the reflected ultrasound energy. Differences in reflected energy (for example, amplitude or frequency) appear as differences in gray scale or color on the output images. As with other medical imaging procedures, contrast media can be injected into the body to increase the difference in the reflected energy and thereby increase the gray scale or color contrast displayed in the image (that is, the image contrast) viewed by the operator. These same properties of an ultrasound contrast medium used to enhance the imaging procedure can also be used to detect extravasation.
Preferably, the second imaging energy source and the sensor are positioned in a manner so that the vicinity of the site is available for palpation and visible for visual inspection. Unlike many other devices for automated detection of extravasation, the energy source(s) and the sensor(s) of the present invention need not be in contact with patient.
It is not necessary that the energy source used in the extravasation detection apparatus of the present invention deliver the same type of energy that is delivered to the region of interest to produce an enhanced image. Indeed, the extravasation detection apparatuses of the present invention are not limited to imaging procedures and can be used in any injection procedure in which there is a potential for extravasation. For example, any injection medium that will reflect, scatter and/or absorb a type of energy can be detected by the extravasation detection apparatuses of the present invention. In general, the presence of such injection media will change the strength of an energy signal that is supplied thereto. For example, any injection medium that contains heavy metal ions is capable of absorbing or scattering X-rays or low energy gamma rays. Such injection media are, for example, used as contrast media in magnetic resonance imaging as well as in CT.
The present invention thus provides a method of detecting extravasation of an injection medium including the steps of supplying energy to tissue in the vicinity of a site and measuring a resultant signal. The energy is preferably selected so that the injection medium will reflect, scatter and/or absorb the energy. Moreover, the energy is preferably chosen to penetrate beyond superficial tissue layers (for example, to a depth greater than ½ inch).
In the case of an injection medium that does not inherently reflect, scatter and/or absorb energy, an additive can be placed in the injection medium to act as an extravasation detection medium. For example, an ultrasound contrast agent can be added to a chemotherapy agent for detection using ultrasonic energy. The present invention thus further provides a method for detecting extravasation in an injection procedure in which an injection medium is injected into a patient that includes the steps of: mixing an additive with the injection medium; supplying energy to tissue in the vicinity of a site; and measuring a signal resulting from the energy supplied to the tissue. The additive is adapted to affect the signal so that extravasation is detectable.
The present invention further provides an injection system including a powered injector and an extravasation detection apparatus. The extravasation detection apparatus includes at least one source of energy to supply energy to tissue in the vicinity of a site and at least one sensor to measure a resultant signal. In general, the signal is proportionate to the energy reflected, scattered and/or absorbed by extravasated fluid in the vicinity of the site.
The present invention also provides an apparatus for the detection of extravasation including at least a first source of X-ray energy or gamma ray energy to supply X-ray energy or gamma ray energy and at least a first sensor to measure a signal resulting from the energy supplied to the tissue. Likewise, the present invention also provides an apparatus for the detection of extravasation including at least a first source of ultrasonic energy to supply ultrasonic energy and at least a first sensor to measure a signal resulting from the ultrasonic energy supplied to the tissue.
The present invention also provides a method for detecting extravasation in an imaging procedure. As discussed above, the imaging procedure generally includes the steps of injecting a contrast medium into a patient and supplying imaging energy to a region of interest of the patient to enhance an image. The method of the present invention includes the steps of: supplying imaging energy to tissue in the vicinity of a site; and measuring a signal resulting from the imaging energy supplied to the tissue.
Likewise, the present invention provides a method for detecting extravasation including the steps of (1) supplying X-ray energy, gamma ray energy and/or ultrasonic energy to tissue in the vicinity of a site, and (2) measuring a signal resulting from the energy supplied to the tissue.
In some patients, extravasation sometimes occurs at a site remote from the catheter insertion point (that is, the injection site). The present invention easily affords the ability to detect extravasation at the injection site and/or any position or site remote from an injection site, but along a path of potential extravasation. Multiple energy sources and/or multiple sensors may be positioned along a path of potential extravasation.
Numerous other advantages are afforded by the apparatuses, systems and methods of the present invention as compared to current apparatuses, systems and methods of detecting extravasation. For example, a larger portion of tissue can be probed for the presence of extravasated injection fluid.
Unlike prior modalities, detection of extravasation in the present invention is not sensitive only in superficial layers of tissue, but can preferably reach through the entire tissue volume into which injection fluid can migrate in the case of extravasation.
Moreover, because contact with the patient is not required in the present invention, the detection site(s) remain open for visualization and/or palpation. Likewise, tight coupling of transducers to the patient's skin and attendant discomfort and/or tissue damage are avoided. The devices of the present invention can also be used in connection with multiple procedures and patients, eliminating the expense and operative inconvenience associated with disposable sensors used in other techniques.
The present invention and its attendant advantages will be further understood by reference to the following detailed description and the accompanying drawings.
In the case that reflected energy is to be measured (for example, in the case of ultrasound energy), energy source 20 and sensor 30 are preferably positioned on the same side of a site. In
During an injection procedure, energy emitted by energy source 20 supplies energy to the tissue of limb 45, and a resultant signal is detected by sensor 30. Unlike prior extravasation detection systems, inherent or designed properties of the injection fluid may be used in the apparatus of the present invention to detect extravasation. For example, injection fluids such as contrast media used in imaging procedures are chosen or designed to respond in a particular manner to imaging energy. For example, the imaging energy may be transformed, reflected, scattered and/or absorbed by a contrast medium. It is this property of a contrast medium that enables enhancement of an image of a region of interest. These and other inherent properties of an injection medium (or an additive thereto) can be used to provide a sensitive detection of extravasation in real time.
Sensor 30 is preferably connected via circuitry 70 (as known in the art) to an alarm device 80 to provide an indication (for example, an audible, visible or tactile indication) to an operator that extravasation is occurring. Circuitry 70 can also be in communicative connection with a powered injector 90 used to pressurize injection fluid contained within a syringe 100 that is in fluid connection with fluid path 60. Detection of extravasation can, for example, result in automatic cessation of the injection procedure by injector 90.
Extravasation device 10 can also be in communicative connection with an imaging system 106. Imaging system 106 may, for example, comprise a source of imaging energy 108 and a signal receiver 110. Receiver 110 is preferably in communicative connection with an imager 112 that may, for example, comprise a processing unit 114 and a display 116. Warning of extravasation can, for example, be displayed on display 116. A record of the occurrence of extravasation can also be maintained on a memory unit of processing unit 114 or another computer system.
Preferably, a fixed geometry is maintained between source 20, sensor 30 and site 40 to ensure consistent measurement. Source 20 and sensor 30 may, for example, be connected in a fixed relationship to each other by a frame 105 that can be positioned in a fixed manner relative to site 40.
Extravasation typically occurs in the immediate vicinity of the injection site. Extravasation may sometimes occur, however, at a site remote from the injection site 40. In the embodiment of
The operation of one embodiment of the present invention will be discussed in further detail with reference to
Gamma ray source 120 can, for example, be any number of long half-life radioisotopes, such as Iodine-129 or Americium-241. Sensors 130 and 130′ can, for example, include a photo multiplier tube, a solid-state detector (such as a cadmium-zinc-telluride or equivalent detector), or another gamma ray detector as known in the art.
Under conditions of no extravasation (as represented by the area on the right side of artery 140 in
When extravasation occurs, as represented by area to the left side of artery 140 in
Because contact with the patient's limb is not required in the present invention, the vicinity of the detection site is maintained in an unobstructed state for palpation and/or visual observation by health care providers.
Although the present invention has been described in detail in connection with the above embodiments and/or examples, it is to be understood that such detail is solely for that purpose and that those skilled in the art can make variations without departing from the invention. The scope of the invention is indicated by the following claims rather than by the foregoing description. All changes and variations that come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a division of application Ser. No. 10/060,561, filed on Jan. 30, 2002 now U.S. Pat. No. 7,047,058, which claims priority to U.S. Provisional Application Ser. No. 60/266,710, filed on Feb. 6, 2001, the contents of which are hereby incorporated by reference
Number | Name | Date | Kind |
---|---|---|---|
3779079 | Snook | Dec 1973 | A |
3951136 | Wall | Apr 1976 | A |
4010749 | Shaw | Mar 1977 | A |
4240445 | Iskander et al. | Dec 1980 | A |
4329689 | Yee | May 1982 | A |
4378808 | Lichtenstein | Apr 1983 | A |
4488559 | Iskander | Dec 1984 | A |
4572182 | Royse | Feb 1986 | A |
4575705 | Gotcher | Mar 1986 | A |
4637929 | Quay | Jan 1987 | A |
4641659 | Sepponen | Feb 1987 | A |
4647281 | Carr | Mar 1987 | A |
4648869 | Bobo, Jr. | Mar 1987 | A |
4653501 | Cartmell et al. | Mar 1987 | A |
4667679 | Sahota | May 1987 | A |
4690149 | Ko | Sep 1987 | A |
4816019 | Kamen | Mar 1989 | A |
4819648 | Ko | Apr 1989 | A |
4877034 | Atkins et al. | Oct 1989 | A |
4923442 | Segall et al. | May 1990 | A |
4959050 | Bobo, Jr. | Sep 1990 | A |
4971068 | Sahi | Nov 1990 | A |
4993409 | Grim | Feb 1991 | A |
5001436 | Scot et al. | Mar 1991 | A |
5026348 | Venegas | Jun 1991 | A |
5184620 | Cudahy et al. | Feb 1993 | A |
5191795 | Fellingham et al. | Mar 1993 | A |
5255683 | Monaghan | Oct 1993 | A |
5334141 | Carr et al. | Aug 1994 | A |
5479927 | Shmulewitz | Jan 1996 | A |
5628322 | Mine | May 1997 | A |
5685305 | Moonen et al. | Nov 1997 | A |
5769784 | Barnett et al. | Jun 1998 | A |
5840026 | Uber, III et al. | Nov 1998 | A |
5861019 | Sun et al. | Jan 1999 | A |
5947910 | Zimmet | Sep 1999 | A |
5954668 | Uber et al. | Sep 1999 | A |
5957950 | Mockros et al. | Sep 1999 | A |
5964703 | Goodman et al. | Oct 1999 | A |
5995863 | Farace et al. | Nov 1999 | A |
6026173 | Svenson et al. | Feb 2000 | A |
6031892 | Karellas | Feb 2000 | A |
6047215 | McClure et al. | Apr 2000 | A |
6061589 | Bridges et al. | May 2000 | A |
6233479 | Haddad et al. | May 2001 | B1 |
6263226 | Axelgaard et al. | Jul 2001 | B1 |
6300906 | Rawnick et al. | Oct 2001 | B1 |
6315719 | Rode et al. | Nov 2001 | B1 |
6332087 | Svenson et al. | Dec 2001 | B1 |
6375624 | Uber, III et al. | Apr 2002 | B1 |
6385483 | Uber, III et al. | May 2002 | B1 |
6397098 | Uber, III et al. | May 2002 | B1 |
6408204 | Hirschman | Jun 2002 | B1 |
6415170 | Loutis et al. | Jul 2002 | B1 |
6425878 | Shekalm | Jul 2002 | B1 |
6454711 | Haddad et al. | Sep 2002 | B1 |
6459931 | Hirschman | Oct 2002 | B1 |
6487428 | Culver et al. | Nov 2002 | B1 |
6520930 | Critchlow et al. | Feb 2003 | B2 |
6673033 | Sciulli et al. | Jan 2004 | B1 |
6704592 | Reynolds et al. | Mar 2004 | B1 |
6751500 | Hirschman | Jun 2004 | B2 |
6970735 | Uber, III et al. | Nov 2005 | B2 |
7047058 | Dvorsky et al. | May 2006 | B1 |
7122012 | Bouton et al. | Oct 2006 | B2 |
7221159 | Griffiths et al. | May 2007 | B2 |
7283860 | Frazier et al. | Oct 2007 | B2 |
7431728 | Gerry et al. | Oct 2008 | B2 |
7457804 | Uber, III et al. | Nov 2008 | B2 |
7591792 | Bouton | Sep 2009 | B2 |
7627710 | Todd et al. | Dec 2009 | B1 |
7632245 | Cowan et al. | Dec 2009 | B1 |
7674244 | Kalafut et al. | Mar 2010 | B2 |
7713239 | Uber, III et al. | May 2010 | B2 |
7937134 | Uber et al. | May 2011 | B2 |
7996381 | Uber, III et al. | Aug 2011 | B2 |
8055328 | Uber, III et al. | Nov 2011 | B2 |
8160679 | Uber et al. | Apr 2012 | B2 |
8182444 | Uber, III et al. | May 2012 | B2 |
8192397 | Griffiths et al. | Jun 2012 | B2 |
8295920 | Bouton et al. | Oct 2012 | B2 |
8307693 | Uram et al. | Nov 2012 | B2 |
8323240 | Wulfman et al. | Dec 2012 | B2 |
8352015 | Bernstein et al. | Jan 2013 | B2 |
8388582 | Eubanks et al. | Mar 2013 | B2 |
8454561 | Uber, III et al. | Jun 2013 | B2 |
8521716 | Uber, III et al. | Aug 2013 | B2 |
20010044588 | Mault | Nov 2001 | A1 |
20020040193 | Hirschman | Apr 2002 | A1 |
20020123674 | Plicchi et al. | Sep 2002 | A1 |
20020172323 | Karellas et al. | Nov 2002 | A1 |
20030004433 | Hirschman | Jan 2003 | A1 |
20030036674 | Bouton | Feb 2003 | A1 |
20030036713 | Bouton et al. | Feb 2003 | A1 |
20040162488 | Uber, III et al. | Aug 2004 | A1 |
20060135884 | Hack et al. | Jun 2006 | A1 |
20060213249 | Uram et al. | Sep 2006 | A1 |
20070056871 | Griffiths et al. | Mar 2007 | A1 |
20070123770 | Bouton et al. | May 2007 | A1 |
20070225601 | Uber, III et al. | Sep 2007 | A1 |
20070244428 | Uram et al. | Oct 2007 | A1 |
20070276327 | Kalafut et al. | Nov 2007 | A1 |
20070282198 | Uber, III et al. | Dec 2007 | A1 |
20070282199 | Uber, III et al. | Dec 2007 | A1 |
20080058758 | Ranchod et al. | Mar 2008 | A1 |
20080097339 | Ranchod et al. | Apr 2008 | A1 |
20080166292 | Levin et al. | Jul 2008 | A1 |
20080167900 | Ranchod | Jul 2008 | A1 |
20080195060 | Roger et al. | Aug 2008 | A1 |
20080294096 | Uber, III et al. | Nov 2008 | A1 |
20090070342 | Uber, III et al. | Mar 2009 | A1 |
20090177050 | Griffiths et al. | Jul 2009 | A1 |
20090247866 | Uber, III et al. | Oct 2009 | A1 |
20090276327 | Malik | Nov 2009 | A1 |
20090299175 | Bernstein et al. | Dec 2009 | A1 |
20090326370 | Uber, III et al. | Dec 2009 | A1 |
20100113887 | Kalafut et al. | May 2010 | A1 |
20100114064 | Kalafut et al. | May 2010 | A1 |
20100174179 | Persson et al. | Jul 2010 | A1 |
20100185040 | Uber, III et al. | Jul 2010 | A1 |
20100198141 | Laitenberger et al. | Aug 2010 | A1 |
20110002802 | Capone et al. | Jan 2011 | A1 |
20110130800 | Weinstein et al. | Jun 2011 | A1 |
20110257522 | Berard-Andersen et al. | Oct 2011 | A1 |
20130062528 | Hyde et al. | Mar 2013 | A1 |
20130079581 | Agamaite et al. | Mar 2013 | A1 |
20130123567 | Agamaite et al. | May 2013 | A1 |
20130123614 | Bernstein et al. | May 2013 | A1 |
20130131585 | Eubanks et al. | May 2013 | A1 |
20130190646 | Weinstein et al. | Jul 2013 | A1 |
20130231550 | Weinstein et al. | Sep 2013 | A1 |
20130253254 | Uber, III et al. | Sep 2013 | A1 |
20130255390 | Riley et al. | Oct 2013 | A1 |
20130331634 | Kaintz et al. | Dec 2013 | A1 |
20130331635 | Hoffman et al. | Dec 2013 | A1 |
20130331810 | Bazala et al. | Dec 2013 | A1 |
20130345676 | Wulfman et al. | Dec 2013 | A1 |
20140046295 | Uber, III et al. | Feb 2014 | A1 |
20140228686 | Bouton | Aug 2014 | A1 |
Number | Date | Country |
---|---|---|
2470801 | Feb 2003 | CA |
100482151 | Apr 2009 | CN |
4007587 | Sep 1991 | DE |
1472973 | Nov 2004 | EP |
1647306 | Apr 2006 | EP |
1675506 | Jun 2010 | EP |
2455402 | May 2012 | EP |
2526857 | Apr 2013 | EP |
2750594 | Jul 2014 | EP |
2750595 | Jul 2014 | EP |
2251080 | Jun 1992 | GB |
11-57001 | Mar 1999 | JP |
2007509353 | Apr 2007 | JP |
WO 9926685 | Jun 1999 | WO |
WO 9926686 | Jun 1999 | WO |
WO 9929356 | Jun 1999 | WO |
WO 0108729 | Feb 2001 | WO |
03009752 | Feb 2003 | WO |
03009753 | Feb 2003 | WO |
WO 03000972 | Feb 2003 | WO |
03063680 | Aug 2003 | WO |
2004036467 | Apr 2004 | WO |
2005043100 | May 2005 | WO |
2008100670 | Aug 2008 | WO |
2009009753 | Jan 2009 | WO |
2010146372 | Dec 2010 | WO |
2011067623 | Jun 2011 | WO |
2011067685 | Jun 2011 | WO |
2012011065 | Jan 2012 | WO |
2012011066 | Jan 2012 | WO |
2012059929 | May 2012 | WO |
2013033162 | Mar 2013 | WO |
2013033166 | Mar 2013 | WO |
2013033174 | Mar 2013 | WO |
2013093923 | Jun 2013 | WO |
2013147799 | Oct 2013 | WO |
Entry |
---|
P. B. James andR. W. Galloway. The ultrasonic blood velocity detector as an aid to arteriography. Br J Radiol Oct. 1971 44:743-746. |
“Value of Multi-Detector Array CT in the Assessment of Portal Hypertension.” Portal Hypertension: Diagnostic Imaging and Imaging-guided Therapy (Medical Radiology/Diagnostic Imaging). Ed. Plinio Rossi. 1st ed. Springer, 2000: p. 111. |
Carr, K.L., “Use of Gallium Arsenide in Medical Applicatgions” IEEE Gallium Arsenide Integrated Circuits (GAAS IC) Symposium, vol. SYMP17, pp. 10-13, New York (Oct. 29, 1995). |
Shaeffer,J.et al.,“Early Detection of Extravastion of Radiographic Contrast Medium,” Radiology, vol. 184, No. 1, pp. 141-144(Jul. 1992). |
Shaeffer, James et al.; Detection of Extravasation of Antineoplastic Drugs by Microwave Radiometry; Cancer Letter, 31; pp. 284-291; 1986; Elsevier Scientific Publishers Ireland Ltd. |
Sukamto, Lin M. et al.; MMIC Receiver for Water-Vapor Radiometer; NASA Tech Briefs; p. 34; Sep. 1993. |
Arkin, H. et al.; Recent Developments in Modeling Heat Transfer in Blood Perfused Tissues; IEEE Transactions on Biomedical Engineering; vol. 41, No. 2; pp. 97-107; Feb. 1994. |
Harris, Thomas S. et al.; Infusion Line Model for the Detection of Infiltration Extravasation, and other Fluid Flow Faults; IEEE Transactions on Biomedical Engineering; vol. 40, No. 2; pp. 154-162; Feb. 1993. |
Montreuil, Jean et al.; Multiangle Method for Temperature Measurement of Biological Tissues by Microwave Radiometry; IEEE Transactions on Microwave Theory and Techniques; vol. 39, No. 7; pp. 1235-1238; Jul. 1991. |
Lin, James C. et al.; Microwave Imaging of Cerebral Edema; Proceedings of the IEEE; vol. 70, No. 5; pp. 523-524; May 1982. |
Kramer, Gerhard G. et al.; Dielectric Measurement of Cerebral Water Content Using a Network Analyzer; Neurological Research; vol. 14, No. 3; pp. 255-258; Sep. 1992. |
Ling, Geoffrey S.F. et al.; Diagnosis of Subdural and Intraparenchymal Intracranial Hemorrhage Using a Microwave Based Detector; Digitization of the Battlespace V and Battlefield Biomedical Technologies II; vol. 4037; pp. 212-217; Apr. 24, 2000. |
Behari, J. et al.; Dielectric Permittivity of Biological Tissues in the Microwave Frequency Range; Proceedings of the SPIE—The International Society for Optical Engineering, Advanced Microwave and Millimeter-Wave Detectors; vol. 2275; pp. 301-308; San Diego, CA; Jul. 25-26, 1994. |
Andreuccetti, D. et al.; High Permittivity Patch Radiator for Single and Multi-Element Hyperthermia Applicators; IEEE Transactions on Biomedical Engineering; vol. 40, No. 7; pp. 711-715; IEEE Inc.; New York; Jul. 1, 1993. |
Lee, Eric R. et al.; Body Conformable 915 MHz Microstrip Array Applicators for Large Surface Area Hyperthermia; IEEE Transactions on Biomedical Engineering; vol. 39, No. 5; pp. 470-438; IEEE Inc., New York; May 1, 1992. |
Jameson, P.; International Search Report; Application No. PCT/US00/20112; Oct. 17, 2000; European Patent Office. |
Van Dooren, G.; International Search Report; Application No. PCT/US02/23877; Feb. 6, 2003; European Patent Office. |
Beitner, M.; International Search Report; Application No. PCT/US02/23925; Jan. 15, 2003; European Patent Office. |
Birnbaum et al. “Extravasation Detection Accessory: Clinical Evaluation in 500 Patients” 1999, Radiology 212:431-438. |
Kent “Hand-Held Instrument for Fat/Water Determination in Whole Fish” 1993, at http://distell.com/products/prd-fish-fatmeter/technical-data/ffm-research-paper. |
European Search Report for EP12005361 dated Mar. 6, 2013. |
Partial European Search Report for EP12005361 dated Nov. 2, 2012. |
Supplementary European Search Report for EP04796177 dated May 11, 2010. |
International Preliminary Report on Patentability and Written Opinion dated Oct. 5, 2005 for PCT/US2004/35135. |
Bouton, Chad E.; Final Office Action; U.S. Appl. No. 13/620,310; Jan. 6, 2014; United States Patent and Trademark Office; Alexandria, VA. |
International Search Report for PCT/US2004/035135 dated Oct. 5, 2005. |
European Search Opinion for EP12005361 dated Mar. 6, 2013. |
Chad E. Bouton; U.S. Appl. No. 14/241,179, filed Mar. 11, 2014 entitled Wireless and Power-Source-Free Extravasation and Infiltration Detection Sensor; United States Patent and Trademark Office; Alexandria, VA (National Stage of PCT/US2012/052801 filed Aug. 29, 2012). |
De la Hera, German; International Search Report and Written Opinion; International Application No. PCT/US2012/052796; Dec. 10, 2012; European Patent Office. |
De la Hera, German; International Search Report and Written Opinion; International Application No. PCT/US2012/052801; Dec. 19, 2012; European Patent Office. |
De la Hera, German; International Search Report and Written Opinion; International Application No. PCT/US2012/052813; Dec. 7, 2012; European Patent Office. |
Chad E. Bouton; U.S. Appl. No. 14/241,171, filed Mar. 11, 2014 entitled Distributed Extravasation Detection System; United States Patent and Trademark Office; Alexandria, VA (National Stage of PCT/U52012/052796 filed Aug. 29, 2012). |
Number | Date | Country | |
---|---|---|---|
60266710 | Feb 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10060561 | Jan 2002 | US |
Child | 11385448 | US |